What Selank actually is

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Moscow. It is a stabilized analogue of tuftsin — a naturally occurring immunomodulatory tetrapeptide — extended with the Pro-Gly-Pro motif also used in Semax.¹

Russian clinical trials report anxiolytic effects comparable to benzodiazepines without sedation, dependence, or cognitive blunting.² The proposed mechanism includes GABAergic modulation, BDNF effects, and serotonergic signaling.

At Luxbae, Selank is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — GABAergic modulation

Modulates GABAergic transmission and serotonergic tone; upregulates BDNF expression in CNS tissue.³

What the research shows

Anxiolytic without sedation. Clinical trials show benzodiazepine-comparable anxiolysis without sedation.²

No dependence pattern. No reported tolerance, withdrawal, or addictive behavior in clinical use.

Cognitive support. Improvements in attention and memory in Russian trials.

Side effects: Generally well-tolerated. Mild nasal irritation, occasional headache, rare drowsiness at high doses.

FDA note: Not FDA-approved. Approved in Russia for anxiety disorders. Prescribed as investigational at Luxbae.

Selank FAQ

Replacement for benzodiazepines?
Not a direct replacement — but anxiolytic effect with cleaner profile.

Will I feel sedated?
Generally no — that’s the appeal.

References

1. Kozlovskaya MM, Kozlovskii II, Vyunova TV, et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior. Neurosci Behav Physiol. 2003.
2. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic, selank. Zh Nevrol Psikhiatr. 2008.
3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression. Dokl Biol Sci. 2008.